This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


CAR T cell therapy may eliminate tumor cells missed by surgery

t cell
Credit: CC0 Public Domain

CAR T cell therapy, an approach which reprograms patients' own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

In the study, published today in Science Advances, the researchers applied a special gel containing human CAR T cells to surgical wounds in mice following partial tumor removal. They found that in almost all cases, the CAR T cells apparently eliminated the residual tumor cells—allowing the mice to survive when they otherwise would have succumbed to tumor recurrence.

Surgery can be curative when a solid tumor cancer has not spread. However, where a tumor ends and healthy tissue begins is often very difficult for surgeons to discern. Thus, for many , post-surgical recurrence due to remaining microscopic tumor cells is common. One possible approach to this problem is to apply an anti-tumor treatment to the remaining tissue margins immediately after tumor removal, to kill any residual tumor cells. In the study, Penn researchers tested that approach using CAR T cells.

"As we continue to advance CAR T cell therapy forward, finding applications for use in solid tumors is a major goal," said study senior author Carl June, MD, the Richard W. Vague Professor in Immunotherapy and director of the Center for Cellular Immunotherapies at Penn Medicine's Abramson Cancer Center. "Based on the promising results in this study, our colleagues have planned a clinical trial in patients with locally advanced breast cancer."

CAR T cells are T cells—a powerful type of immune cell—that are engineered to target specific proteins. All the CAR T treatments that have been approved for clinical use target proteins found on cancer cells. Typically, the T cells are harvested from the patient's blood, engineered in the lab, and then put back into the patient to work as a "living drug."

June and colleagues at Penn helped develop and test what became, in 2017, the first U.S. Food and Drug Administration-approved CAR T treatment. There are now six approved CAR T cell therapies targeting a variety of , which have provided fresh hope for patients who have run out of conventional options.

Solid tumors, so far, have been a harder target for CAR T treatments, due in part to tumor bulk and tumor anti-immune defenses. However, another group of researchers showed in a study last year, in a mouse model of brain cancer, that CAR T cells might be useful for the more limited task of clearing up residual after surgery.

In the new study, June and colleagues tried this same approach against two other cancer types: , which lacks all of the three major breast cancer markers, and human pancreatic ductal carcinoma, the most common type of pancreatic cancer. Both of these solid tumor types are notoriously hard to cure.

The CAR T cells were engineered to home in on the protein mesothelin, a surface marker on both types of tumor cell in the experiments. Without the CAR T cell and fibrin gel, the remaining tumor tissue grew and the mice succumbed within about seven weeks. With the gel, however, residual tumor tissue swiftly disappeared in 19 of 20 mice, and these animals survived without wound-healing complications or other apparent side effects for the remainder of the observation period.

Further experiments showed that CAR T cells targeting mesothelin have the potential to attack bearing that protein marker after , and the toxicity was decreased by local injection of the CAR T cells compared to direct injection of the cells into the blood.

"This study demonstrates the promise of CAR T as an add-on to surgery for ," June said. "We also think that this approach could be broadened to deliver other cellular therapies and anticancer agents in addition to CAR T cells, potentially boosting the antitumor effectiveness even further."

More information: Ugur Uslu et al, Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma, Science Advances (2023). DOI: 10.1126/sciadv.ade2526.

Journal information: Science Advances
Citation: CAR T cell therapy may eliminate tumor cells missed by surgery (2023, January 11) retrieved 22 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Targeting one type of immune cell with another slows cancer growth in preclinical studies


Feedback to editors